Track Record of Revenue and Profit Growth
First written in FY2016. . Latest entry: FY2026.
- FY2026Higher revenue, operating income, ordinary income and net incomeAnnual report
「Revenue for the current consolidated fiscal year was ¥116,951 million, up 11.2% year on year. Operating profit was ¥10,147 million, up 24.9%. Ordinary profit was ¥11,195 million, up 38.8%, and net income attributable to owners of the parent was ¥7,903 million, up 39.0%.」
Following higher revenue and earnings in FY2025, revenue, operating profit, ordinary profit, and net income attributable to owners of the parent in FY2026 also exceeded the previous fiscal year. - FY2026-H1Higher revenue, operating income, ordinary income and net incomeAnnual report
「Revenue for the current interim consolidated fiscal period was ¥54,985 million, up 7.6% year on year. On the earnings side, operating profit was ¥4,967 million, up 31.0% year on year, due to higher gross profit accompanying increased revenue from the pharmaceutical-related business. Ordinary profit was ¥5,179 million, up 27.0%, and interim net income attributable to owners of the parent was ¥3,856 million, up 36.5%.」
During the current interim consolidated fiscal period, revenue, operating profit, ordinary profit, and interim net income attributable to owners of the parent all exceeded the year-earlier levels. - FY2025Higher revenue, operating income, ordinary income and net incomeAnnual report
「Revenue for the current consolidated fiscal year was ¥105,159 million, up 2.2% year on year. Operating profit was ¥8,126 million, up 40.1%. Ordinary profit was ¥8,067 million, up 33.6%, and net income attributable to owners of the parent was ¥5,685 million, up 25.0%.」
After lower revenue and earnings in FY2024, FY2025 saw revenue, operating profit, ordinary profit, and net income attributable to owners of the parent all exceed the previous fiscal year. - FY2025-H1Revenue up, operating profit down, ordinary profit up, net income downAnnual report
「Revenue for the current interim consolidated fiscal period was ¥51,096 million, up 3.3% year on year. On the earnings side, operating profit was ¥3,793 million, down 4.0% year on year, due mainly to a higher cost-of-sales ratio resulting from drug price revisions and higher import prices for active pharmaceutical ingredients and finished products resulting from the weaker yen. Ordinary profit was ¥4,079 million, up 0.6%, while interim net income attributable to owners of the parent was ¥2,825 million, down 0.5%.」
Revenue increased 3.3% year on year, operating profit fell 4.0%, ordinary profit increased 0.6%, and interim net income attributable to owners of the parent fell 0.5%. - FY2024Lower revenue, lower operating profit, lower ordinary profit and lower net incomeAnnual report
「Revenue for the current consolidated fiscal year was ¥102,885 million, down 0.4% year on year. On the earnings side, gross profit declined due to lower revenue from the pharmaceutical-related business and higher import prices for active pharmaceutical ingredients and finished products resulting from the weaker yen. Selling expenses also increased in connection with the launch of new products. Operating profit was ¥5,802 million, down 31.8% year on year. Ordinary profit was ¥6,037 million, down 33.5%, and net income attributable to owners of the parent was ¥4,547 million, down 31.6%.」
In FY2024, revenue fell 0.4%, operating profit fell 31.8%, ordinary profit fell 33.5%, and net income attributable to owners of the parent fell 31.6%. - FY2024-Q3Lower revenue, lower operating profit, lower ordinary profit and lower net incomeAnnual report
「Revenue for the first nine months of the current consolidated fiscal year was ¥78,218 million, down 3.9% year on year. On the earnings side, gross profit declined due to lower revenue from the pharmaceutical-related business and higher import prices for active pharmaceutical ingredients and finished products resulting from the weaker yen. Selling expenses also increased. Operating profit was ¥5,791 million, down 44.1% year on year. Ordinary profit was ¥6,059 million, down 43.0%, and net income attributable to owners of the parent was ¥4,444 million, down 45.0%.」
Revenue, operating profit, ordinary profit, and net income attributable to owners of the parent all declined year on year. Lower pharmaceutical-related revenue, higher import prices resulting from the weaker yen, and higher selling expenses were cited as factors behind the decline in earnings. - FY2024-Q2Lower revenue, lower operating profit, lower ordinary profit and lower net incomeAnnual report
「Revenue for the first six months of the current consolidated fiscal year was ¥49,476 million, down 7.0% year on year. On the earnings side, gross profit declined due to lower revenue from the pharmaceutical-related business and higher import prices for active pharmaceutical ingredients and finished products resulting from the weaker yen. Operating profit was ¥3,952 million, down 25.1% year on year. Ordinary profit was ¥4,053 million, down 25.5%, and net income attributable to owners of the parent was ¥2,838 million, down 27.6%.」
Revenue, operating profit, ordinary profit, and net income attributable to owners of the parent all declined year on year. Lower pharmaceutical-related revenue and higher import prices resulting from the weaker yen were cited as factors behind the decline in earnings. - FY2024-Q1Lower revenue, lower operating profit, lower ordinary profit and lower net incomeAnnual report
「Revenue for the first quarter of the current consolidated fiscal year was ¥24,747 million, down 10.6% year on year. On the earnings side, gross profit declined as revenue from the pharmaceutical-related business fell. Operating profit was ¥2,515 million, down 41.0% year on year. Ordinary profit was ¥2,592 million, down 41.3%, and net income attributable to owners of the parent was ¥1,688 million, down 46.5%.」
Revenue, operating profit, ordinary profit, and net income attributable to owners of the parent all declined year on year. The decline in gross profit accompanying lower revenue from the pharmaceutical-related business was cited as a factor behind the decline in earnings. - FY2023Lower revenue, lower operating profit, lower ordinary profit and lower net incomeAnnual report
「Revenue for the current consolidated fiscal year was ¥103,261 million, down 6.3% year on year. On the earnings side, gross profit declined as revenue from the pharmaceutical-related business fell, while selling, general and administrative expenses exceeded the previous fiscal year, primarily due to higher research and development expenses. Operating profit was ¥8,507 million, down 40.9% year on year. Ordinary profit was ¥9,085 million, down 38.6%, and net income attributable to owners of the parent was ¥6,649 million, down 37.1%.」
After higher revenue and earnings in FY2022, FY2023 saw revenue, operating profit, ordinary profit, and net income attributable to owners of the parent all fall below the previous fiscal year. - FY2023-Q3Lower revenue, lower operating profit, lower ordinary profit and lower net incomeAnnual report
「Revenue for the first nine months of the current consolidated fiscal year was ¥81,394 million, down 4.0% year on year. On the earnings side, gross profit declined as revenue from the pharmaceutical-related business fell. Operating profit was ¥10,356 million, down 20.6% year on year. Ordinary profit was ¥10,639 million, down 20.9%, and net income attributable to owners of the parent was ¥8,081 million, down 20.6%.」
Revenue, operating profit, ordinary profit, and net income attributable to owners of the parent all declined year on year. - FY2023-Q2Lower revenue, lower operating profit, lower ordinary profit and lower net incomeAnnual report
「Revenue for the first six months of the current consolidated fiscal year was ¥53,200 million, down 1.5% year on year. On the earnings side, gross profit declined as revenue from the pharmaceutical-related business fell, while selling, general and administrative expenses exceeded the year-earlier level. Operating profit was ¥5,279 million, down 13.9% year on year. Ordinary profit was ¥5,443 million, down 14.6%, and net income attributable to owners of the parent was ¥3,923 million, down 20.2%.」
Revenue, operating profit, ordinary profit, and net income attributable to owners of the parent all declined year on year. - FY2023-Q1Higher revenue, operating income, ordinary income and net incomeAnnual report
「Revenue for the first quarter of the current consolidated fiscal year was ¥27,692 million, up 1.2% year on year. On the earnings side, gross profit increased as revenue from the pharmaceutical-related business grew, while selling, general and administrative expenses fell below the year-earlier level, primarily due to lower research and development expenses. Operating profit was ¥4,265 million, up 34.0% year on year, and ordinary profit was ¥4,415 million, up 31.2%. Net income attributable to owners of the parent was ¥3,155 million, up 18.9%.」
Revenue, operating profit, ordinary profit, and net income attributable to owners of the parent all increased year on year. - FY2022Higher revenue, operating income, ordinary income and net incomeAnnual report
「Revenue for the current consolidated fiscal year was ¥110,179 million, up 7.0% year on year. Operating profit was ¥14,392 million, up 19.9%, ordinary profit was ¥14,799 million, up 20.7%, and net income attributable to owners of the parent was ¥10,569 million, up 23.1%.」
Revenue and earnings increased for the second consecutive year following FY2021, with revenue, operating profit, ordinary profit, and net income attributable to owners of the parent all exceeding the previous fiscal year. - FY2022-Q3Higher revenue, operating income, ordinary income and net incomeAnnual report
「Revenue for the first nine months of the current consolidated fiscal year was ¥84,814 million, up 6.2% year on year. On the earnings side, selling, general and administrative expenses increased, primarily due to higher research and development expenses, but gross profit increased as revenue from the pharmaceutical-related business grew. As a result, operating profit was ¥13,045 million, up 16.6% year on year, and ordinary profit was ¥13,447 million, up 17.7%. Net income attributable to owners of the parent was ¥10,180 million, up 21.1%.」
Revenue, operating profit, ordinary profit, and net income attributable to owners of the parent all exceeded the year-earlier levels. The company shifted from higher revenue but lower operating profit in the previous third quarter to higher revenue and earnings. - FY2022-Q2Higher revenue, lower operating profit, lower ordinary profit and lower net incomeAnnual report
「Revenue for the first six months of the current consolidated fiscal year was ¥54,009 million, up 4.6% year on year. On the earnings side, gross profit increased as revenue from the pharmaceutical-related business grew, but selling, general and administrative expenses, mainly research and development expenses, also increased. Operating profit was ¥6,131 million, down 15.2% year on year, and ordinary profit was ¥6,377 million, down 13.6%. Net income attributable to owners of the parent was ¥4,916 million, down 9.1%.」
Revenue increased year on year, while operating profit, ordinary profit, and net income attributable to owners of the parent all declined. The increase in selling, general and administrative expenses, mainly research and development expenses, was cited as a factor behind the decline in earnings. - FY2022-Q1Lower revenue, lower operating profit, lower ordinary profit and lower net incomeAnnual report
「Revenue for the first quarter of the current consolidated fiscal year was ¥27,362 million, down 0.1% year on year. On the earnings side, gross profit increased due to a lower cost-of-sales ratio, but selling, general and administrative expenses, mainly research and development expenses, increased. Operating profit was ¥3,183 million, down 30.7% year on year, and ordinary profit was ¥3,366 million, down 28.9%. Net income attributable to owners of the parent was ¥2,653 million, down 21.2%.」
Revenue, operating profit, ordinary profit, and net income attributable to owners of the parent all declined year on year. The increase in selling, general and administrative expenses, mainly research and development expenses, was cited as a factor behind the decline in operating profit and other earnings. - FY2021Higher revenue, operating income, ordinary income and net incomeAnnual report
「Revenue for the current consolidated fiscal year was ¥102,995 million, up 1.2% year on year. On the earnings side, gross profit increased due to a lower cost-of-sales ratio. In addition, selling, general and administrative expenses declined due to the impact of COVID-19 and other factors. As a result, operating profit was ¥12,003 million, up 36.3% year on year, and ordinary profit was ¥12,260 million, up 33.9%. Net income attributable to owners of the parent was ¥8,587 million, up 86.8%.」
For the full year, revenue, operating profit, ordinary profit, and net income attributable to owners of the parent all exceeded the previous fiscal year, shifting from lower revenue and earnings to higher revenue and earnings. - FY2021-Q3Higher revenue, operating income, ordinary income and net incomeAnnual report
「Revenue for the first nine months of the current consolidated fiscal year was ¥79,881 million, up 1.0% year on year. On the earnings side, gross profit increased due to a lower cost-of-sales ratio. In addition, selling, general and administrative expenses declined due to the impact of COVID-19 and other factors. As a result, operating profit was ¥11,184 million, up 33.9% year on year, and ordinary profit was ¥11,428 million, up 32.0%. Net income attributable to owners of the parent was ¥8,407 million, up 31.8%.」
Revenue, operating profit, ordinary profit, and net income attributable to owners of the parent all increased year on year. Lower cost of sales and lower selling, general and administrative expenses were cited as factors behind the increase in earnings. - FY2021-Q2Higher revenue, operating income, ordinary income and net incomeAnnual report
「Revenue for the first six months of the current consolidated fiscal year was ¥51,623 million, up 0.2% year on year. On the earnings side, gross profit increased due to a lower cost-of-sales ratio. In addition, selling, general and administrative expenses declined, primarily because of lower research and development expenses. As a result, operating profit was ¥7,229 million, up 16.6% year on year, and ordinary profit was ¥7,385 million, up 15.5%. Net income attributable to owners of the parent was ¥5,411 million, up 17.8%.」
Revenue increased modestly, while operating profit, ordinary profit, and net income attributable to owners of the parent all exceeded the year-earlier levels. - FY2021-Q1Higher revenue, operating income, ordinary income and net incomeAnnual report
「Revenue for the first quarter of the current consolidated fiscal year was ¥27,379 million, up 3.4% year on year. On the earnings side, gross profit increased as revenue from the pharmaceutical-related business grew. Selling, general and administrative expenses increased due to higher research and development expenses. As a result, operating profit was ¥4,594 million, up 1.7% year on year, and ordinary profit was ¥4,736 million, up 1.5%. Net income attributable to owners of the parent was ¥3,367 million, up 1.9%.」
Revenue, operating profit, ordinary profit, and net income attributable to owners of the parent all increased year on year. The first quarter shifted to higher revenue and earnings from the declining revenue and earnings trend in the previous fiscal year and the previous first quarter. - FY2020Lower revenue, lower operating profit, lower ordinary profit and lower net incomeAnnual report
「Revenue for the current consolidated fiscal year was ¥101,799 million, down 7.2% year on year, due mainly to the impact of policies to restrain pharmaceutical costs in the pharmaceutical-related business. Operating profit was ¥8,807 million, down 16.8%, ordinary profit was ¥9,154 million, down 16.2%, and net income attributable to owners of the parent was ¥4,598 million, down 45.5%.」
For the full year, revenue, operating profit, ordinary profit, and net income attributable to owners of the parent all fell below the previous fiscal year. - FY2020-Q3Lower revenue, lower operating profit, lower ordinary profit and lower net incomeAnnual report
「Revenue for the first nine months of the current consolidated fiscal year was ¥79,097 million, down 9.7% year on year, due mainly to the impact of measures promoting the use of generic drugs in the pharmaceutical-related business. On the earnings side, gross profit declined as pharmaceutical-related revenue fell, while selling, general and administrative expenses exceeded the year-earlier level. Operating profit was ¥8,353 million, down 26.0% year on year, and ordinary profit was ¥8,655 million, down 25.3%. Net income attributable to owners of the parent was ¥6,378 million, down 35.2%, partly due to a decrease in extraordinary income and other factors.」
For the first nine months, revenue, operating profit, ordinary profit, and net income attributable to owners of the parent all fell below the year-earlier levels. - FY2020-Q2Lower revenue, lower operating profit, lower ordinary profit and lower net incomeAnnual report
「Revenue for the first six months of the current consolidated fiscal year was ¥51,512 million, down 10.0% year on year, due mainly to the impact of measures promoting the use of generic drugs in the pharmaceutical-related business. On the earnings side, gross profit declined as revenue from the pharmaceutical-related business fell. Operating profit was ¥6,200 million, down 18.7% year on year, and ordinary profit was ¥6,393 million, down 17.6%. Net income attributable to owners of the parent was ¥4,592 million, down 33.8%, partly due to a decrease in extraordinary income and other factors.」
For the first six months, revenue, operating profit, ordinary profit, and net income attributable to owners of the parent all fell below the year-earlier levels. The decline in pharmaceutical-related revenue due to measures promoting the use of generic drugs, lower gross profit, and lower extraordinary income and other factors were cited. - FY2020-Q1Lower revenue, lower operating profit, lower ordinary profit and lower net incomeAnnual report
「As a result, revenue for the first quarter of the current consolidated cumulative period was ¥26,488 million, down 11.1% year on year, due mainly to the impact of measures promoting the use of generic drugs in the pharmaceutical-related business. On the earnings side, gross profit declined as revenue from the pharmaceutical-related business fell. Operating profit was ¥4,519 million, down 26.7% year on year, and ordinary profit was ¥4,666 million, down 25.8%. Net income attributable to owners of the parent was ¥3,305 million, down 43.4%, partly due to a decrease in extraordinary income and other factors.」
Revenue, operating profit, ordinary profit, and net income attributable to owners of the parent all declined year on year. The decline in pharmaceutical-related revenue due to measures promoting the use of generic drugs, as well as the decrease in extraordinary income and other factors, was cited. - FY2019Higher revenue, lower operating profit, lower ordinary profit and lower net incomeAnnual report
「Revenue for the current consolidated fiscal year was ¥109,643 million, up 2.7% year on year. Operating profit was ¥10,590 million, down 9.2%, ordinary profit was ¥10,928 million, down 9.0%, and net income attributable to owners of the parent was ¥8,435 million, down 6.5%.」
For the full year, revenue increased, while operating profit, ordinary profit, and net income attributable to owners of the parent all fell below the previous fiscal year. - FY2019-Q3Higher net sales, lower operating and ordinary income, and higher net incomeAnnual report
「As a result, revenue for the first nine months of the current consolidated fiscal year was ¥87,638 million, up 4.7% year on year. On the earnings side, the cost-of-sales ratio rose due to the impact of drug price revisions and other factors, resulting in lower gross profit. In addition, selling, general and administrative expenses exceeded the year-earlier level due mainly to higher research and development expenses. Operating profit was ¥11,286 million, down 7.6% year on year, and ordinary profit was ¥11,582 million, down 7.3%. Net income attributable to owners of the parent was ¥9,849 million, up 6.2% year on year, due in part to the recognition of extraordinary income from a settlement payment related to the interpretation of a contract concerning raw material prices.」
For the first nine months, revenue increased 4.7% year on year, while operating profit fell 7.6% and ordinary profit fell 7.3%. Net income attributable to owners of the parent increased 6.2% due to the recognition of extraordinary income from a settlement payment. - FY2019-Q2Higher net sales, lower operating and ordinary income, and higher net incomeAnnual report
「As a result, revenue for the first six months of the current consolidated fiscal year was ¥57,236 million, up 4.9% year on year. On the earnings side, the cost-of-sales ratio increased due to the impact of drug price revisions and other factors, but gross profit increased as revenue grew. However, selling, general and administrative expenses exceeded the year-earlier level, primarily because of higher research and development expenses. Operating profit was ¥7,622 million, down 5.8% year on year, and ordinary profit was ¥7,756 million, down 6.2%. Net income attributable to owners of the parent was ¥6,936 million, up 17.1% year on year, due in part to the recognition of extraordinary income from a settlement payment related to the interpretation of a contract concerning raw material prices.」
Revenue increased 4.9% year on year, while operating profit fell 5.8% and ordinary profit fell 6.2%. Net income attributable to owners of the parent increased 17.1% due to the recognition of extraordinary income from a settlement payment. - FY2019-Q1Higher revenue, operating income, ordinary income and net incomeAnnual report
「As a result, revenue for the first quarter of the current consolidated cumulative period was ¥29,800 million, an increase of 2.7% year on year. On the earnings side, although drug price revisions had an impact, gross profit increased due mainly to contributions from royalty income and other factors. In addition, selling, general and administrative expenses were below the year-earlier level, primarily because of lower research and development expenses. Operating profit was ¥6,167 million, up 3.6% year on year, and ordinary profit was ¥6,286 million, up 3.1%. Net income attributable to owners of the parent was ¥5,843 million, up 35.3% year on year, due in part to the recognition of extraordinary income from a settlement payment related to the interpretation of a contract concerning raw material prices.」
Revenue, operating profit, ordinary profit, and net income attributable to owners of the parent all exceeded the year-earlier levels. Net income included extraordinary income from a settlement payment related to the interpretation of a contract concerning raw material prices. - FY2018Higher revenue, operating income, ordinary income and net incomeAnnual report
「Revenue for the current consolidated fiscal year amounted to ¥106.761 billion, an increase of 9.7% year on year, as the pharmaceutical-related business generally performed steadily despite the impact of policies to curb drug costs, while the healthcare business also remained firm. In terms of earnings, revenue increased, but gross profit declined due to a change in the product mix of the pharmaceutical-related business. Meanwhile, selling, general and administrative expenses declined from the previous fiscal year, mainly due to lower research and development expenses, resulting in operating profit of ¥11.662 billion, up 2.5% year on year; ordinary profit of ¥12.008 billion, up 3.1%; and net income attributable to owners of the parent of ¥9.023 billion, up 5.8%.」
For the full year, revenue, operating profit, ordinary profit, and net income attributable to owners of the parent all exceeded the previous fiscal year. - FY2018-Q3Higher revenue, lower operating profit, lower ordinary profit and lower net incomeAnnual report
「As a result, revenue for the first nine months of the current fiscal year amounted to ¥8.3730 billion, an increase of 14.6% year on year. In terms of earnings, selling, general and administrative expenses fell below the prior-year level, mainly due to lower research and development expenses, but gross profit declined due to a change in the product mix of the pharmaceutical-related business. Operating profit declined 6.7% to ¥12.209 billion, ordinary profit declined 6.2% to ¥12.496 billion, and net income attributable to owners of the parent declined 5.4% to ¥9.270 billion.」
Revenue increased 14.6% year on year, but operating profit, ordinary profit and net income attributable to owners of the parent all declined. The decline in gross profit due to a change in the product mix is explained as the main factor affecting earnings. - FY2018-Q2Higher revenue, operating income, ordinary income and net incomeAnnual report
「As a result, revenue for the first six months of the current fiscal year amounted to ¥5.4588 billion, an increase of 17.6% year on year. In terms of earnings, gross profit declined due to a change in the product mix of the pharmaceutical-related business, but selling, general and administrative expenses fell below the prior-year level, mainly due to lower research and development expenses. Operating profit increased 11.9% to ¥8.089 billion, ordinary profit increased 10.8% to ¥8.266 billion, and net income attributable to owners of the parent increased 6.5% to ¥5.922 billion.」
Net sales, operating profit, ordinary profit and net income attributable to owners of the parent all increased year on year. - FY2018-Q1Substantial revenue growth, higher operating profit, higher ordinary profit and higher net incomeAnnual report
「As a result, revenue for the first quarter of the current fiscal year amounted to ¥2.9011 billion, an increase of 18.4% year on year. In terms of earnings, gross profit increased with higher revenue from the pharmaceutical-related business, while selling, general and administrative expenses fell below the prior-year level, mainly due to lower research and development expenses. Operating profit increased 44.6% to ¥5.954 billion, ordinary profit increased 41.2% to ¥6.097 billion, and net income attributable to owners of the parent increased 31.9% to ¥4.318 billion.」
Revenue, operating profit, ordinary profit and net income attributable to owners of the parent all increased year on year, and the increases in revenue and profit expanded compared with the cumulative results for the previous quarter. - FY2017-Q3Higher revenue, operating income, ordinary income and net incomeAnnual report
「As a result, revenue for the first nine months of the current fiscal year amounted to ¥7.3037 billion, an increase of 1.2% year on year. In terms of earnings, selling, general and administrative expenses increased, mainly due to higher research and development expenses, but gross profit rose with higher revenue from the pharmaceutical-related business. Operating profit increased 9.3% to ¥13.088 billion, ordinary profit increased 9.6% to ¥13.328 billion, and net income attributable to owners of the parent increased 16.6% to ¥9.795 billion.」
For the nine months ended December 31, revenue, operating profit, ordinary profit and profit attributable to owners of the parent all exceeded the levels of the same period of the previous fiscal year. - FY2017-Q2Higher revenue, operating income, ordinary income and net incomeAnnual report
「As a result, revenue for the first six months of the current fiscal year amounted to ¥4.6426 billion, an increase of 2.3% year on year. In terms of earnings, selling, general and administrative expenses increased, mainly due to higher research and development expenses, but gross profit rose with higher revenue from the pharmaceutical-related business. Operating profit increased 2.4% to ¥7.232 billion, ordinary profit increased 3.6% to ¥7.458 billion, and net income attributable to owners of the parent increased 15.5% to ¥5.562 billion.」
For the cumulative second quarter, revenue, operating profit, ordinary profit and net income attributable to owners of the parent all exceeded the same period of the previous year. - FY2017-Q1Higher net sales, lower operating and ordinary income, and higher net incomeAnnual report
「As a result, revenue for the first quarter of the current fiscal year amounted to ¥2.4508 billion, an increase of 8.2% year on year. In terms of earnings, gross profit increased with higher revenue from the pharmaceutical-related business, but operating profit declined 4.6% year on year to ¥4.117 billion because selling, general and administrative expenses increased, mainly due to higher research and development expenses. Ordinary profit declined 2.3% to ¥4.317 billion. Net income attributable to owners of the parent increased 2.4% to ¥3.275 billion, mainly due to the impact of tax reforms and other factors.」
Revenue and net income attributable to owners of the parent increased year on year, while operating profit and ordinary profit declined, resulting in a different earnings trend from the previous fiscal year's increase in both revenue and profit. - FY2016First statedAnnual report
「Revenue amounted to ¥92.272 billion, an increase of 5.8% year on year, as the pharmaceutical-related business generally performed steadily despite the impact of policies to curb drug costs, while the healthcare business also remained firm.」
Operating profit was ¥12.154 billion, up 4.0% year on year; ordinary profit was ¥12.392 billion, up 4.1%; and net income attributable to owners of the parent was ¥8.150 billion, up 8.0%.